Skip to main navigation Skip to search Skip to main content

Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis

  • on behalf of the Ovarian Cancer Association Consortium
  • , on behalf of the AOCS Group
  • University of Pittsburgh
  • Peter Maccallum Cancer Centre
  • The Westmead Institute for Medical Research
  • National Institutes of Health
  • University of Queensland
  • Radboud University Nijmegen
  • Netherlands Comprehensive Cancer Organisation
  • University of California at Irvine
  • Rutgers - The State University of New Jersey, New Brunswick
  • Friedrich-Alexander University Erlangen-Nürnberg
  • Duke University
  • Provincial Health Services Authority
  • German Cancer Research Center
  • University of Hamburg
  • Colorado School of Public Health
  • University of Calgary
  • Harvard University
  • Fred Hutchinson Cancer Research Center
  • University of Utah
  • Cedars-Sinai Medical Center
  • University College London
  • Cancer Council Victoria
  • University of Melbourne
  • Monash University
  • Mayo Clinic Rochester, MN
  • University of Washington
  • University of Toronto
  • California State University Fullerton
  • Aichi Cancer Center Hospital and Research Institute
  • Nagoya University
  • Stanford University
  • University of Michigan, Ann Arbor
  • Memorial Sloan-Kettering Cancer Center
  • University of Southern California
  • University of New South Wales
  • Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre
  • Icahn School of Medicine at Mount Sinai
  • Emory University
  • University of South Florida
  • Public Health

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Background: The role of ovulation in epithelial ovarian cancer (EOC) is supported by the consistent protective effects of parity and oral contraceptive use. Whether these factors protect through anovulation alone remains unclear. We explored the association between lifetime ovulatory years (LOY) and EOC. Methods: LOY was calculated using 12 algorithms. Odds ratios (ORs) and 95% confidence intervals (CIs) estimated the association between LOY or LOY components and EOC among 26 204 control participants and 21 267 case patients from 25 studies. To assess whether LOY components act through ovulation suppression alone, we compared beta coefficients obtained from regression models with expected estimates assuming 1 year of ovulation suppression has the same effect regardless of source. Results: LOY was associated with increased EOC risk (OR per year increase = 1.014, 95% CI = 1.009 to 1.020 to OR per year increase = 1.044, 95% CI = 1.041 to 1.048). Individual LOY components, except age at menarche, also associated with EOC. The estimated model coefficient for oral contraceptive use and pregnancies were 4.45 times and 12- to 15-fold greater than expected, respectively. LOY was associated with high-grade serous, low-grade serous, endometrioid, and clear cell histotypes (ORs per year increase = 1.054, 1.040, 1.065, and 1.098, respectively) but not mucinous tumors. Estimated coefficients of LOY components were close to expected estimates for high-grade serous but larger than expected for low-grade serous, endometrioid, and clear cell histotypes. Conclusions: LOY is positively associated with nonmucinous EOC. Differences between estimated and expected model coefficients for LOY components suggest factors beyond ovulation underlie the associations between LOY components and EOC in general and for non-HGSOC.

Original languageEnglish
Pages (from-to)539-551
Number of pages13
JournalJournal of the National Cancer Institute
Volume115
Issue number5
DOIs
StatePublished - May 1 2023

Fingerprint

Dive into the research topics of 'Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis'. Together they form a unique fingerprint.

Cite this